Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the exchanges that the members of the management team of the Company will attend 'Nuvama India Conference 2023' on February 08, 2023 (Wednesday), at The St. Regis, Mumbai, and will meet the investors. Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Earnings Call held on January 27, 2023 on the Unaudited Financial Results (Standalone and Consolidated) of Anupam Rasayan India Limited for the quarter and nine months ended December 31, 2022 Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of newspaper advertisement clippings pertaining to the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022
Anupam Rasayan India Results Earnings Call for Q3FY23
Conference Call with Anupam Rasayan India Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript. Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Earnings Call on Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022 Q3FY23 Quarterly Result Announced for Anupam Rasayan India Ltd.
Agrochemicals firm Anupam Rasayan Indian announced Q3FY23 results: Q3FY23: Operating revenues at Rs 3,827 million in Q3FY23 as compared to Rs 2,662 million in Q3FY22 – growth of 44% YoY. Total revenues at Rs 3,888 million in Q3FY23 as compared to Rs 2,711 million in Q3FY22 – growth of 43% YoY. EBITDA (incl. other revenue) at Rs 1,080 million in Q3FY23 as compared to Rs 800 million in Q3FY22 – growth of 35% YoY. Profit After Tax at Rs 544 million in Q3FY23 as compared to Rs 379 million in Q3FY22 - growth of 44% YoY. Anand Desai, Managing Director of Anupam Rasayan, commented, “I am pleased to inform you that despite unavailability of the certain capacities during the quarter, we were able to deliver growth on YoY basis. If you adjust the deferred revenue due to capacity constrain then our growth would have been around 25% during the quarter. I am delighted to share that we have received approval to restart the plant from the GPCB and other regulatory authorities after following all the regulatory and safety compliances. This shows our unwavering focus on compliance and maintaining high levels of manufacturing and safety standards, which has helped us get the closure order lifted within a shorter time span. We continue to strengthen our business development team as we have a strong pipeline of products to launch in coming quarters. Our customer interactions remain very encouraging, and we have specifically seen strong interest from various customers on the fluorination side. Overall, our strong pipeline of products, availability of the capacity, advance stage discussion with various clients along with capex which is moving ahead of the plan makes me confident of delivering strong and sustainable growth in coming quarters and years.” Result PDF Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Investor Presentation
'Investor Presentation' in respect of the unaudited financial results for the quarter and nine months ended December 31, 2022 Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release Intimation dated January 27, 2023, titled "Reports Q3FY23 Results" Anupam Rasayan India Ltd - 543275 - The Board Fixes The Record Date
The Board has fixed the Record Date for the payment of the 2nd interim dividend as February 08, 2023 Anupam Rasayan India Ltd - 543275 - Financial Results For The Quarter And Nine Months Ended December 31, 2022
The Board of Directors of the Company in its meeting held today i.e. January 27, 2023, have approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022